Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone31-0-30-253-8800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.36 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/25/2019 (Estimated)
OptionableNot Optionable
Merus (NASDAQ:MRUS) Frequently Asked Questions
What is Merus' stock symbol?
Merus trades on the NASDAQ under the ticker symbol "MRUS."
How were Merus' earnings last quarter?
Merus NV (NASDAQ:MRUS) posted its earnings results on Thursday, December, 27th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter. The biotechnology company earned $7.57 million during the quarter, compared to analyst estimates of $4.25 million. Merus had a negative net margin of 140.49% and a negative return on equity of 55.96%. View Merus' Earnings History.
When is Merus' next earnings date?
What price target have analysts set for MRUS?
2 equities research analysts have issued 1 year target prices for Merus' stock. Their predictions range from $16.00 to $34.00. On average, they expect Merus' share price to reach $25.00 in the next twelve months. This suggests a possible upside of 94.7% from the stock's current price. View Analyst Price Targets for Merus.
What is the consensus analysts' recommendation for Merus?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.
Has Merus been receiving favorable news coverage?
Media headlines about MRUS stock have trended somewhat positive on Saturday, according to InfoTrie. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Merus earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
Who are some of Merus' key competitors?
Some companies that are related to Merus include Spectrum Pharmaceuticals (SPPI), Epizyme (EPZM), Tricida (TCDA), Homology Medicines (FIXX), Inflarx (IFRX), Ra Pharmaceuticals (RARX), Rhythm Pharmaceuticals (RYTM), Clementia Pharmaceuticals (CMTA), Retrophin (RTRX), Amphastar Pharmaceuticals (AMPH), Vanda Pharmaceuticals (VNDA), MacroGenics (MGNX), Dicerna Pharmaceuticals (DRNA), Kiniksa Pharmaceuticals (KNSA) and Deciphera Pharmaceuticals (DCPH).
What other stocks do shareholders of Merus own?
Who are Merus' key executives?
Merus' management team includes the folowing people:
- Ton Logtenberg, President, Chief Executive Officer & Director
- John J. Crowley, Chief Financial Officer & Executive Vice President
- John de Kruif, Chief Technology Officer & Senior Vice President
- Mark Throsby, Chief Scientific Officer & Executive VP
- L. Andres Sirulnik, Chief Medical Officer & Executive Vice President
When did Merus IPO?
(MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
Who are Merus' major shareholders?
Merus' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Tekla Capital Management LLC (1.62%), Artal Group S.A. (0.91%), RMB Capital Management LLC (0.11%), Geode Capital Management LLC (0.07%), Geode Capital Management LLC (0.07%) and Squarepoint Ops LLC (0.05%).
Which institutional investors are selling Merus stock?
MRUS stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC and RMB Capital Management LLC.
Which institutional investors are buying Merus stock?
MRUS stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., Geode Capital Management LLC, Geode Capital Management LLC and Squarepoint Ops LLC.
How do I buy shares of Merus?
Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merus' stock price today?
One share of MRUS stock can currently be purchased for approximately $12.84.
How big of a company is Merus?
Merus has a market capitalization of $292.11 million and generates $15.36 million in revenue each year. The biotechnology company earns $-82,610,000.00 in net income (profit) each year or ($4.29) on an earnings per share basis.
What is Merus' official website?
How can I contact Merus?
Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]
MarketBeat Community Rating for Merus (NASDAQ MRUS)
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
